A male patient who sustained a cervical spinal cord injury in a car accident ten years ago, and whose hand-grasping function had been stagnant through years of standardised rehabilitation, received an epidural brain-computer interface implant at Shanghai Huashan Hospital on Monday 13 July 2026.

The device is Neuracle NEO. The company, product, and surgery all sit inside four months of Chinese regulatory and reimbursement machinery that ran from the 13 March 2026 NMPA approval through the 28 April 2026 Huashan insurance filing, the Shanghai Huahui Bao commercial supplementary insurance inclusion, provincial pricing frameworks in Hubei, Sichuan, Zhejiang, and Beijing that Inside BCI covered on 4 July 2026, and the 11 June 2026 acceptance of Neuracle’s STAR Market IPO prospectus that Inside BCI covered on 22 June 2026.

The surgery is not the first NEO implantation in a human. Neuracle ran a 36-participant multicentre clinical trial programme from October 2023 through early 2026 (4 feasibility participants plus 32 confirmatory participants across Xuanwu Hospital in Beijing, Beijing Tiantan Hospital, and Huashan Hospital in Shanghai; ClinicalTrials.gov identifier NCT06990412) that produced the safety and efficacy data underlying the March NMPA approval. The 13 July 2026 procedure is the first commercial implantation of the device: performed after the NMPA product registration, after National Healthcare Security Administration coding, after Shanghai municipal listing on 24 March 2026, and after Huashan’s own medical insurance pricing filing on 28 April 2026. That is the specific step Chinese state media are describing as world-first.

The device and the patient

The NEO system consists of two coin-sized processors implanted through micro-holes in the skull and positioned on the dura mater surface above the primary sensorimotor cortex. The implants do not penetrate cortical tissue. The device is epidural, not intracortical. The system uses eight physical electrode channels; Neuracle describes its proprietary decoding algorithms as resolving those eight physical channels into a larger set of virtual channels for motor decoding purposes. The implant is wirelessly powered through an external magnetic coil and contains no internal battery. Titanium shell sealing carries the company’s stated operational-life target of twenty or more years, though the longest actual chronic clinical follow-up as of the July 2026 commercial surgery is approximately two years and nine months from the October 2023 first-in-human procedure at Xuanwu Hospital.

The regulatory-registered indication for NEO is patients with tetraplegia caused by cervical spinal cord injury. The commercial surgery on 13 July 2026 was performed in an adult male patient who sustained cervical SCI in a car accident approximately ten years earlier. The patient retained some upper-arm function but had impaired hand-grasping capacity that had been resistant to standardised rehabilitation. He was selected through a multidisciplinary Huashan Hospital screening process against the registered indication. Per the Huashan release relayed via Xinhua, intraoperative epidural EEG signals were reported as stable and of good quality, and the patient’s post-operative vital signs were stable. Neither age nor patient identity has been disclosed publicly. The functional target is hand-grasping restoration through a pneumatic glove actuated by the decoded neural signals.

Two named clinicians and one named company executive appear in the announcements. Mao Ying, President of Huashan Hospital, described the launch as the world’s first clinical cohort study of BCIs based on the 32-participant confirmatory registration trial and a six-month neurological rehabilitation evaluation. Wu Zehan, a neurosurgeon at Huashan Hospital, is named in China Daily’s second write-up of the surgery. Wang Yujing, Neuracle’s marketing director, is also cited in China Daily.

The procedure was performed at Huashan Hospital’s neurosurgery service, which is one of three National Neurological Disease Medical Centers in China. Rehabilitation protocol as disclosed by the hospital runs at six hours per day for more than one month before functional improvements become significant.

Neuracle Technology, its Tsinghua lineage, and its STAR Market IPO run-up

The developer of NEO is Neuracle Technology (Shanghai) Co., Ltd. (Chinese legal entity: 博睿康技术（上海）股份有限公司), which trades under the Boruikang (博睿康) brand family. The company was founded in 2011 out of Tsinghua University’s Neural Engineering Lab. The two co-founders are Xu Honglai, who holds a doctorate in biomedical engineering from Tsinghua, and Huang Xiaoshan, who holds a bachelor’s in biomedical engineering from Tsinghua. Both were students of Professor Gao Shangkai (高上凯), a foundational figure in Chinese BCI research. The NEO device’s academic partner is Professor Hong Bo (洪波) and his team at Tsinghua’s School of Biomedical Engineering.

Neuracle’s Chinese corporate entity re-registered to Shanghai’s Zhangjiang Science City in Pudong in 2025 as part of its STAR Market listing preparation, retaining historic operating footprint in Changzhou (Jiangsu) at the Sino-German Industrial Innovation and Cooperation Center and in Beijing at the original Tsinghua incubation base. The company operates from Neuro Space, the Shanghai BCI industry cluster launched in June 2025 in southwestern Shanghai.

The STAR Market IPO prospectus was accepted by the Shanghai Stock Exchange on 11 June 2026, per Inside BCI’s 22 June 2026 coverage, with CITIC Securities as sponsor. The prospectus is filed under the STAR Market’s fifth listing standard, which permits pre-profit listings on a four-year clock. Neuracle is targeting a raise of approximately RMB 2.5 billion through the IPO. The company’s most recent private funding round valued Neuracle at approximately RMB 4 billion post-money (~US$550-590 million). Financials disclosed in the prospectus report revenue of RMB 75.21 million in 2023, RMB 65.97 million in 2024, and RMB 108 million in 2025 (the first year Neuracle crossed the RMB 100 million revenue threshold), with cumulative 2023-2025 losses of approximately RMB 328 million. Prior venture backers named across public disclosures include Sequoia China, Songhe Capital (formerly Cowin Capital, 松禾资本), and China Merchants China Fund. Inside BCI’s earlier reporting also mentioned Baidu Ventures as a backer; that participation is not verified in the current prospectus disclosures available to Inside BCI and is therefore omitted here.

The race for the informal title of Chinese BCI first-listed stock (脑机接口第一股) is between Neuracle on the Shanghai STAR Market and BrainCo on the Hong Kong Stock Exchange. BrainCo confidentially filed for a Hong Kong listing in January 2026 per Bloomberg, with CICC and UBS Group as arrangers. Inside BCI covered the CNBC video profile of BrainCo’s Nyx He on 10 July 2026. Manycore Tech, another of Hangzhou’s Six Little Dragons, completed its Hong Kong IPO in April 2026, which means BrainCo is not on track to be the first of the Hangzhou Six to trade publicly. Whether Neuracle reaches STAR Market trading before BrainCo reaches Hong Kong trading is a specific commercial race worth tracking.

Where this fits in China’s four-month post-approval commercialisation timeline

The 13 March 2026 NMPA Class III approval of NEO was itself the world’s first regulatory clearance of a commercial invasive BCI medical device, granted under the NMPA’s fast-track pathway for breakthrough medical devices. Within approximately 48 hours of the March approval, the National Healthcare Security Administration issued NEO-specific billing codes. Within about a week, Shanghai’s medical insurance green channel processed NEO. On 24 March 2026 the device was officially listed. On 28 April 2026 Huashan Hospital completed its own medical insurance pricing filing. The Shanghai Huahui Bao 2026 Edition commercial supplementary insurance included NEO consumables at 30 per cent reimbursement up to an annual cap of ¥150,000 (approximately US$21,000 per Yicai’s own conversion). The Huahui Bao is a Shanghai-only commercial supplementary programme; it is not the national basic medical insurance, and it is not the same mechanism as the provincial invasive-BCI-procedure pricing frameworks that Hubei, Sichuan, Zhejiang, and Beijing had already published earlier in 2026 and that Inside BCI covered on 4 July 2026 as part of the NMPA Announcement No. 24 classification piece.

The estimated total cost of an NEO commercial procedure, per Paradromics’ April 2026 industry analysis, is approximately RMB 300,000 to 500,000 (~US$41,000 to US$69,000) for device, surgery, calibration, and rehabilitation. That estimate predates the 13 July commercial surgery. Whether the Huashan procedure’s actual billed amount matches the estimated range, and how the ¥150,000 Huahui Bao cap plus any provincial-tier reimbursement leaves the patient’s out-of-pocket cost, are practical questions that will surface as more procedures are performed and pricing data emerges.

The four-month interval between the March NMPA approval and the July first commercial procedure is itself the specific operational signal about how quickly the Chinese medical device commercialisation system is now moving on BCI. NMPA approval, national billing coding, municipal listing, hospital insurance filing, commercial supplementary insurance inclusion, and first paid procedure all fit in less than eighteen weeks. That is faster than the pace at which the equivalent US pathway (FDA PMA approval, Medicare National Coverage Determination, private-payer coverage, and hospital contracting) typically runs on comparable Class III neurotechnology, and it is the reason Chinese state media are treating today’s Huashan procedure as a symbolic industrial-policy milestone rather than a single clinical event.

Where this sits in the industrial-builder posture

Inside BCI’s ongoing coverage identifies four global BCI regulatory postures: the rights-first Chile (constitutional neurorights), the horizontal-regulator European Union (AI Act and GDPR), the state-patchwork United States (Colorado, California, Montana, Connecticut), and the industrial-builder China (with South Korea). The 13 July Huashan procedure is the industrial-builder posture producing its first commercial clinical output. The NMPA classification framework of Announcement No. 24 (2026) that Inside BCI covered on 4 July 2026 (every implantable BCI Class III, one narrow Class II lane for non-invasive non-AI stroke motor rehabilitation) is now translating from device-classification framework into an actual commercially implanted and provincially reimbursed device.

The Chinese SCI patient population, according to Beijing News figures cited by Global Times, is approximately 3.7 million people with a spinal cord injury, with approximately 90,000 new cases per year and approximately 70 per cent of SCI patients under 50 at the time of injury. That is the specific addressable-market size for NEO’s registered indication. Neuracle’s stated commercial plan runs from these initial post-approval surgeries at Huashan through additional hospital sites during 2026 and 2027. Chinese state media have cited a projection of the Chinese BCI market at approximately RMB 6.14 billion by 2028, per China Center for Information Industry Development (CCID Consulting) under the Ministry of Industry and Information Technology.

What to watch

Watch the pace and geographic distribution of the second, third, and tenth NEO commercial implants. The 13 July procedure is one patient at one site. Whether the second commercial NEO implant lands at Huashan, at Beijing Tiantan Hospital, at Xuanwu Hospital in Beijing, or at a new hospital that has completed its own insurance pricing filing will indicate whether Neuracle is running a single-anchor commercial rollout or a distributed rollout across the existing Neuracle EFS trial-site network.

Watch the Neuracle STAR Market listing pricing and first-day-of-trading date. The 11 June 2026 prospectus acceptance is the starting gun; the SSE listing committee review, CSRC registration, price-range announcement, and first-day-of-trading are the remaining regulatory-and-market steps. Whether Neuracle lists ahead of BrainCo’s Hong Kong pricing is a specific race with strategic implications for Chinese BCI capital allocation.

Watch whether the NMPA’s Announcement No. 24 BCI classification framework attracts any additional commercial invasive BCI approvals in the coming twelve months. As of publication, NEO is the only commercially approved invasive BCI under the specific NMPA BCI medical device classification. Whether NeuroXess, StairMed, NeuCyber, or another Chinese invasive BCI company receives NMPA approval next will indicate whether the Chinese commercial BCI category is a Neuracle monopoly or a competitive market.

Watch the international response. Neuralink confirmed at least 21 enrolled participants in its cohort at the end of January 2026 per Reuters, with tracker estimates approaching 26 by mid-2026 across US, UK, UAE, and Canadian trial arms, none of them commercial. Paradromics announced its first Connexus implant in 2026 at University of Michigan Health, and Onward Medical, Precision Neuroscience, Synchron, ABILITY Neurotech, and Epia Neuro all remain in clinical-trial stage. Whether any of them accelerates a regulatory pathway in response to Neuracle’s commercial reach, and whether US Committee on Foreign Investment or Department of Commerce Entity List activity around Chinese BCI companies changes in response, are downstream commercial-policy signals to track.

Sources

• Xinhua: China’s brain-computer interface sector achieves accelerating progress (16 July 2026)
• Yicai Global: Shanghai Hospital Performs World’s First Commercial BCI Implant Surgery Using Homegrown Device (15 July 2026)
• CGTN: Shanghai hospital completes world’s first BCI for hand movement (16 July 2026)
• Global Times: Shanghai hospital completes China’s first commercial BCI surgery (15 July 2026)
• China Daily: Shanghai hospital completes world’s first BCI for hand movement using Chinese device (15 July 2026)
• SCMP: China completes world’s first commercial brain-computer interface implant (15 July 2026)
• Gizmodo: China Just Performed the World’s First Implant of a Commercial Brain-Computer Interface (15 July 2026)
• Nature Biotechnology: China approves brain chip to overcome paralysis (News in Brief, 17 April 2026, DOI 10.1038/s41587-026-03101-8)
• Paradromics blog: China’s Recent BCI Developments and What They Mean for the US (April 2026, updated 2 July 2026)
• ClinicalTrials.gov NCT06990412: Neuracle NEO tetraplegia trial
• Inside BCI: Neuracle STAR Market IPO prospectus accepted (22 June 2026) · NMPA Announcement No. 24 BCI classification framework (4 July 2026) · Gestala ultrasound BCI Angel+ Shanghai HQ (3 July 2026) · Beijing Changfazhan BCI incubation platform + Shanghai financing (7 July 2026) · CNBC BrainCo Nyx He (10 July 2026) · BCI vertical broadening synthesis (13 July 2026)